Efficacy and Safety of Topical GT20029 in Male Patients With Androgenetic Alopecia: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study
January 2025
TLDR Topical GT20029 effectively promotes hair regrowth and is well-tolerated for treating androgenetic alopecia.
The study evaluated the efficacy and safety of topical GT20029 in 180 male patients with androgenetic alopecia through a multicenter, randomized, double-blind, placebo-controlled phase 2 trial. Participants were divided into groups receiving different concentrations and frequencies of GT20029 or a placebo. The results showed variations in hair growth metrics, such as terminal hair to vellus hair ratio and total hair count, across the different treatment groups. All participants had a history of androgenetic alopecia, with varying disease durations. The study provides insights into the potential of GT20029 as a treatment for hair loss, though specific efficacy outcomes are not detailed in the provided data.
